Salk Polio Vaccine Declared Safe and Effective

Context

Poliomyelitis had plagued human populations for millennia, but the disease emerged as a terrifying public-health crisis in the United States during the first half of the twentieth century. Recurrent summer epidemics left thousands of children paralyzed or dependent on iron lungs, prompting school closures, travel restrictions, and widespread parental anxiety. President Franklin D. Roosevelt’s own paralysis after contracting the virus in 1921 helped focus national attention and resources on the problem.

What Happened

Virologist Jonas Salk at the University of Pittsburgh developed an inactivated-virus vaccine with funding from the National Foundation for Infantile Paralysis, also known as the March of Dimes. In 1954 the foundation launched an unprecedented double-blind field trial involving nearly two million schoolchildren, monitored by epidemiologist Thomas Francis Jr. at the University of Michigan’s Poliomyelitis Vaccine Evaluation Center.

Aftermath

On April 12, 1955—exactly ten years after Roosevelt’s death—Francis announced the results at a press conference in Rackham Auditorium in Ann Arbor. He declared the vaccine “safe, effective, and potent,” with strong protection against paralytic disease and no serious side effects. Licensing was granted the same day, and pharmaceutical production began immediately. Spontaneous celebrations erupted across the country as the news spread by radio and wire services.

Legacy

Widespread vaccination campaigns quickly followed, and U.S. polio cases fell sharply within a few years. The event established the modern model of large-scale, rigorously controlled vaccine trials and demonstrated the effectiveness of coordinated philanthropy, academic research, and government oversight. It also paved the way for Albert Sabin’s oral vaccine and ongoing global eradication efforts under the World Health Organization.